ENDRA Life Sciences (NDRA) Return on Equity (2017 - 2026)

ENDRA Life Sciences has disclosed Return on Equity across 10 years of filings, most recently posting 0.04% for Q1 2026.

• In Q1 2026, Return on Equity rose 1.0% year-over-year to 0.04%; the TTM figure through Mar 2026 stood at 0.04% (up 1.0% YoY), while the FY2025 annual figure was 0.03%, changed 0.0% from the prior year.
• Return on Equity advanced to 0.04% in Q1 2026, from 0.06% in the prior quarter.
• Over the last five years, Return on Equity for NDRA reached as high as 0.01% in Q2 2022 and fell as low as 0.1% in Q3 2025.
• The 5-year median for Return on Equity is 0.02% (2024), against an average of 0.03%.
• Annual changes were most pronounced in 2024 — Return on Equity rose 1 bps — and 2025, when it dropped 9 bps.
• A 5-year view of Return on Equity shows it stood at 0.02% in 2022, then decreased by 22 bps to 0.02% in 2023, then plunged by 35 bps to 0.03% in 2024, then plunged by 130 bps to 0.06% in 2025, then jumped by 38 bps to 0.04% in 2026.
• According to Business Quant data, Return on Equity over the past three periods registered 0.04%, 0.06%, and 0.1% for Q1 2026, Q4 2025, and Q3 2025 respectively.